Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Pembrolizumab in Patients With High Risk, Stage IIB/IIC Cutaneous Melanoma: a Single Arm Proof of Concept Phase IIA Study.

NCT07883759 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Besancon as lead sponsor.

NCT NCT07883759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07883759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Pembrolizumab in Patients With High Risk, Stage IIB/IIC Cutaneous Melanoma: a Single Arm Proof of Concept Phase IIA Study.
Lead sponsor
Centre Hospitalier Universitaire de Besancon
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
November 30, 2030
Enrollment
19 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

stage iib melanoma, stage iic melanoma